Pregnolia

Pregnolia has developed a measurement and diagnostic tool that helps doctors to significantly better assess the risk of premature birth. Up to 1 in 10 babies in developed countries are born too early, each costing USD 50’000 in hospital stays. Pregnolia’s patented technology doubles the rate of detection of mothers at risk of premature birth, as compared with the current gold standard procedure. The device measures the cervical tissue structure using a probe, producing a reading in seconds. With Pregnolia’s tool, obstetricians know better when to intervene to reduce the risk of early delivery.
Dr. Sabrina Badir about Verve Ventures
Verve Venture's trust in Pregnolia's vision was key for the last two financing rounds and we are grateful to belong to the VERVE Ventures portofolio!
Founders / Management Dr. Sabrina Badir, Dr. Francisco Delgado
Sectors Health & Bio, Diagnostics, Medical Devices
Located in Switzerland
Co-Investors Cadfem, ZKB
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.